Cardiovascular disease continues to be the leading cause of death worldwide. But advances in heart-failure therapeutics have ...

Pluristyx's iPSC platform provides therapeutic developers with a streamlined path from research to clinical application, offering high-quality, regulatory-compliant starting materials and advanced ...

Next-Generation Biopharmaceuticals Transforming the Global Therapeutic LandscapeThe Global Bio Pharmaceuticals Market is ...

Researchers can use messenger RNA to trigger the immune system to attack tumors. By stimulating cancer cells to produce a ...

New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and ...

People looking to lose weight and lower their blood sugar may someday be able to get a single injection that turns their ...

Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...

In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated ...

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...

The start of the trial marks an expansion of the firm's oncology pipeline, and the firm hopes mRNA-2808 will be the first of many T-cell engagers in its portfolio.